That's my thoughts too, I'm hoping to see some more...

That's my thoughts too, I'm hoping to see some more mature data from the Hervaxx Phase 2 study that was presented to the AACR, as they did mention "Additional" information would be presented and this info would definitely be price sensitive, hence the requirement for an ASX release. I believe that most of the movement late last week was driven by the PD1 announcement, which in itself is huge for IMU. I believe it means we will be progressing to phase 2 regardless of the outcome of the 3rd cohort as we have already shown safety and efficacy at 50ug if there are adverse results at 100ug then phase 2 will stick with 50ug. after all phase 1a is only about understanding the best dosage. Great results from the Hervaxx study will just be the boost we need to break through the 20c barrier IMO
Good luck to all holders